Orlistat 120 mg

DRUG4 trials

Sponsors

Shionogi, Fifth Affiliated Hospital of Xinjiang Medical University, Ping Peng, XueMei Guo

Conditions

GoutHyperlipidemiaLung AdenocarcinomaObesityOsimertinib

Phase 2

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

CompletedNCT01126970

ShionogiObesity

Start: 2010-04-30End: 2011-02-28Updated: 2018-05-09

Orlistat Overcoming Third-generation EGFR-TKI Resistance

Not yet recruitingNCT06818955

Ping PengLung Adenocarcinoma, Osimertinib

Start: 2025-02-16End: 2025-11-15Target: 36Updated: 2025-02-12

Unknown Phase

Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia.

Fifth Affiliated Hospital of Xinjiang Medical UniversityHyperlipidemia

Start: 2019-04-01End: 2019-09-30Target: 58Updated: 2019-03-21

Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT

Not yet recruitingNCT07326839

XueMei GuoGout, Obesity

Start: 2025-12-10End: 2027-11-09Target: 120Updated: 2026-01-08